M D Coates1, I Tekin2, K E Vrana3, G M Mawe4. 1. Department of Medicine, Division of Gastroenterology & Hepatology, Penn State Hershey Medical Center, Hershey, PA, USA. 2. Neuroscience Institute, University of California at Santa Barbara, Santa Barbara, CA, USA. 3. Department of Pharmacology, Penn State College of Medicine, Hershey, PA, USA. 4. Department of Neurological Sciences, University of Vermont College of Medicine, Burlington, VT, USA.
Abstract
BACKGROUND: Serotonin (5-hydroxytryptamine, 5-HT) is an important mediator of every major gut-related function. Recent investigations also suggest that 5-HT can influence the development and severity of inflammation within the gut, particularly in the setting of inflammatory bowel disease (IBD). AIM: To review the roles that the intestinal serotonin signalling system plays in gut function, with a specific focus on IBD. METHODS: We reviewed manuscripts from 1952 to 2017 that investigated and discussed roles for 5-HT signalling in gastrointestinal function and IBD, as well as the influence of inflammation on 5-HT signalling elements within the gut. RESULTS: Inflammation appears to affect every major element of intestinal 5-HT signalling, including 5-HT synthesis, release, receptor expression and reuptake capacity. Importantly, many studies (most utilising animal models) also demonstrate that modulation of selective serotonergic receptors (via agonism of 5-HT4 R and antagonism of 5-HT3 R) or 5-HT signal termination (via serotonin reuptake inhibitors) can alter the likelihood and severity of intestinal inflammation and/or its complicating symptoms. However, there are few human studies that have studied these relationships in a targeted manner. CONCLUSIONS: Insights discussed in this review have strong potential to lead to new diagnostic and therapeutic tools to improve the management of IBD and other related disorders. Specifically, strategies that focus on modifying the activity of selective serotonin receptors and reuptake transporters in the gut could be effective for controlling disease activity and/or its associated symptoms. Further studies in humans are required, however, to more completely understand the pathophysiological mechanisms underlying the roles of 5-HT in this setting.
BACKGROUND:Serotonin (5-hydroxytryptamine, 5-HT) is an important mediator of every major gut-related function. Recent investigations also suggest that 5-HT can influence the development and severity of inflammation within the gut, particularly in the setting of inflammatory bowel disease (IBD). AIM: To review the roles that the intestinal serotonin signalling system plays in gut function, with a specific focus on IBD. METHODS: We reviewed manuscripts from 1952 to 2017 that investigated and discussed roles for 5-HT signalling in gastrointestinal function and IBD, as well as the influence of inflammation on 5-HT signalling elements within the gut. RESULTS:Inflammation appears to affect every major element of intestinal 5-HT signalling, including 5-HT synthesis, release, receptor expression and reuptake capacity. Importantly, many studies (most utilising animal models) also demonstrate that modulation of selective serotonergic receptors (via agonism of 5-HT4 R and antagonism of 5-HT3 R) or 5-HT signal termination (via serotonin reuptake inhibitors) can alter the likelihood and severity of intestinal inflammation and/or its complicating symptoms. However, there are few human studies that have studied these relationships in a targeted manner. CONCLUSIONS: Insights discussed in this review have strong potential to lead to new diagnostic and therapeutic tools to improve the management of IBD and other related disorders. Specifically, strategies that focus on modifying the activity of selective serotonin receptors and reuptake transporters in the gut could be effective for controlling disease activity and/or its associated symptoms. Further studies in humans are required, however, to more completely understand the pathophysiological mechanisms underlying the roles of 5-HT in this setting.
Authors: B Lavoie; J A Roberts; M M Haag; S N Spohn; K G Margolis; K A Sharkey; J B Lian; G M Mawe Journal: Pharmacol Res Date: 2018-07-17 Impact factor: 7.658
Authors: Eriton E L Valente; James L Klotz; Gyuchul Ahn; Kyle R McLeod; Hannah M Herzing; Mindy King; David L Harmon Journal: J Anim Sci Date: 2020-12-01 Impact factor: 3.159
Authors: Lai Wei; Rajan Singh; Se Eun Ha; Alyce M Martin; Lauren A Jones; Byungchang Jin; Brian G Jorgensen; Hannah Zogg; Tyler Chervo; Andres Gottfried-Blackmore; Linda Nguyen; Aida Habtezion; Nick J Spencer; Damien J Keating; Kenton M Sanders; Seungil Ro Journal: Gastroenterology Date: 2021-03-02 Impact factor: 33.883
Authors: Luis Alberto Bravo-Vázquez; Ixchel Medina-Ríos; Luis David Márquez-Gallardo; Josué Reyes-Muñoz; Francisco I Serrano-Cano; Surajit Pathak; Antara Banerjee; Anindya Bandyopadhyay; Asim K Duttaroy; Sujay Paul Journal: Dig Dis Sci Date: 2022-05-04 Impact factor: 3.487
Authors: M Carmen Louzao; Celia Costas; Paula Abal; Toshiyuki Suzuki; Ryuichi Watanabe; Natalia Vilariño; Cristina Carrera; Andrea Boente-Juncal; Carmen Vale; Mercedes R Vieytes; Luis M Botana Journal: Arch Toxicol Date: 2021-06-20 Impact factor: 5.153